Document:

Exhibit
4.4

 

DESCRIPTION
OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT

TO
SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

As
of February 24, 2022, Provention Bio, Inc. (the “Company”) had one class of common stock registered under Section 12 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

The
following description of the Company’s common stock is a summary and does not purport to be complete. It is subject to and qualified
in its entirety by reference to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate
of Incorporation”) and the Company’s Amended and Restated Bylaws (the “Bylaws”), each of which is incorporated
herein by reference as an exhibit to the Annual Report on Form 10-K filed with the Securities and Exchange Commission, of which this
Exhibit 4.4 is a part. The Company encourages you to read its Certificate of Incorporation, its Bylaws and the applicable provisions
of the General Corporation Law of the State of Delaware (the “DGCL”) for additional information.

 

Authorized
Capital Stock

 

The
Company’s authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share and 25,000,000 shares
of preferred stock, par value $0.0001 per share.

 

Common
Stock

 

Holders
of the Company’s common stock are entitled to such dividends as may be declared by its board of directors, or any authorized committee
thereof, out of funds legally available for such purpose, subject to the preferences applicable to any series of preferred stock outstanding
at any time. The shares of common stock are neither redeemable nor convertible. Holders of common stock have no preemptive or subscription
rights to purchase any of the Company’s securities.

 

Each
holder of common stock is entitled to one vote for each such share outstanding in the holder’s name. No holder of common stock
is entitled to cumulate votes in voting for directors.

 

Subject
to any preferential rights of outstanding shares of preferred stock, if any, holders of common stock will share ratably in all assets
legally available for distribution to the Company’s stockholders in the event of the Company’s liquidation, dissolution or
winding up, after payments of all debts and other liabilities. All of the outstanding shares of common stock are fully paid and non-assessable.

 

Listing

 

The
Company’s common stock is listed on the Nasdaq Global Select Market under the symbol “PRVB.”

 

Transfer
Agent and Registrar

 

The
transfer agent and registrar for the Company’s common stock is Broadridge Corporate Issuers Solutions, Inc. Its address is 51 Mercedes
Way, Edgewood, New York 11717.

 

Anti-Takeover
Effects of Delaware Law and Certificate of Incorporation and Bylaws

 

Certain
provisions of Delaware law, the Certificate of Incorporation and Bylaws could have the effect of delaying, deferring or discouraging
another party from acquiring control of the Company. These provisions, which are summarized below, encourage persons seeking to acquire
control of the Company to first negotiate with the Company’s board of directors and the holders of the Company’s capital
stock.

 

    	 

     

    

 

Undesignated
Preferred Stock

 

The
ability to authorize undesignated preferred stock makes it possible for the Company’s board of directors to issue preferred stock
with voting or other rights or preferences that could impede the success of any attempt to acquire the Company. These and other provisions
may have the effect of deferring hostile takeovers or delaying changes in control or management of the Company.

 

Stockholder
Action; Special Meeting of Stockholders

 

The
Certificate of Incorporation and Bylaws provide that stockholders may act by written consent. However, stockholders pursuing an action
by written consent will be required to comply with certain notice and record date requirements that are set forth in the Bylaws and the
DGCL. A special meeting of stockholders may be called by the chairperson of the board of directors, the chief executive officer, the
president (in the absence of the chief executive officer) or the board of directors at any time and for any purpose or purposes as shall
be stated in the notice of the meeting. A special meeting of stockholders may also be called at the request of the holders of record
of at least 20% of the Company’s outstanding shares of common stock. This provision may prevent stockholders from calling a special
meeting because, unless certain significant stockholders were to join with them, they might not obtain the percentage necessary to request
the meeting. Therefore, stockholders holding less than 20% of the Company’s outstanding shares of common stock, without the assistance
of management, may be unable to propose a vote on any transaction, which may delay, defer or prevent a change of control.

 

Requirements
for Advance Notification of Stockholder Nominations and Proposals

 

The
Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors,
other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In addition, the
Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These
provisions may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate
of directors or otherwise attempting to obtain control of the Company.

 

Super-Majority
Voting

 

The
DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s
certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires
a greater percentage. The Bylaws may be amended or repealed by a majority vote of the board of directors or the affirmative vote of the
holders of at least 66 2/3% of the total voting power of outstanding voting securities. In addition, the affirmative vote of the holders
of at least 66 2/3% of the voting power of the outstanding shares of the capital stock entitled to vote thereon is required to amend,
repeal or to adopt any provisions of the Certificate of Incorporation that are inconsistent with, among others, the provisions relating
to the general powers of the board of directors, the number and election of directors, the filling of vacancies on the board of directors,
the ability of the board of directors to adopt, amend or repeal the Bylaws, the ability to call special stockholder meetings, director
liability and director and officer indemnification.

 

Board
of Directors

 

The
Certificate of Incorporation authorizes the board of directors to, by a resolution of the majority of the board of directors, fix the
number of directors from time to time and to appoint new directors to fill any vacancies. The limitations on the ability of the Company’s
stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third
party to acquire, or discourage a third party from seeking to acquire, control of the Company.

 

    	 

     

    

 

Exclusive
Forum

 

The
Certificate of Incorporation requires, unless the Company’s consents in writing to the selection of an alternative forum, that
the Court of Chancery in the State of Delaware will be the sole and exclusive forum for any stockholder to bring (i) any derivative action
or proceeding brought on the Company’s behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of the
Company’s directors, officers or other employees to the Company or the Company’s stockholders, (iii) any action asserting
a claim against the Company, its directors, officers or employees arising pursuant to any provision of the DGCL or the Certificate of
Incorporation or Bylaws or (iv) any action asserting a claim against the Company, its directors, officers or employees governed by the
internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that
there is an indispensable party not subject to the jurisdiction of the Court of Chancery, which is vested in the exclusive jurisdiction
of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Although
the Company believes this provision benefits the Company by providing increased consistency in the application of Delaware law in the
types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against the Company’s directors
and officers.

 

Delaware
Law

 

The
Company is subject to Section 203 of the DGCL. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging
in any business combination with any interested stockholder for three years following the date that the stockholder became an interested
stockholder, unless:

 

	 	●	prior
    to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
    which resulted in the stockholder becoming an interested stockholder;
	 	 	 
	 	●	upon
    completion of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes
    of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned
    by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject
    to the plan will be tendered in a tender or exchange offer; or
	 	 	 
	 	●	on
    or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an
    annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
    voting stock which is not owned by the interested stockholder.

 

Generally,
a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested
stockholder. An interested stockholder is any person who, together with such person’s affiliates and associates (i) owns 15% or
more of a corporation’s voting securities or (ii) is an affiliate or associate of a corporation and was the owner of 15% or more
of the corporation’s voting securities at any time within the three-year period immediately preceding a business combination of
the corporation governed by Section 203. The Company expects the existence of this provision to have an anti-takeover effect with respect
to transactions the Company’s board of directors does not approve in advance. The Company also anticipates that Section 203 may
discourage takeover attempts that might result in a premium over the market price for the shares of common stock held by the Company’s
stockholders.Exhibit
10.22

 

November
1, 2021

 

VIA
EMAIL

Andrew
Drechsler

 

Dear
Andy:

 

This
letter agreement (this “Agreement”) confirms the terms of the remainder of your employment with Provention Bio, Inc.
(the “Company”) and your engagement as a consultant by the Company, as follows:

 

	1.	Transition Period.

 

(a)
Transition. Subject to earlier termination as provided herein, from the date hereof through December 31, 2021 (the actual date
of your termination of employment, the “Separation Date”), you will continue to serve as the Company’s Chief
Financial Officer; provided that, on and after such date as a new Chief Financial Officer commences employment with the Company,
you will serve as Special Advisor to the Chief Executive Officer of the Company (the “CEO”) and the Chief Financial
Officer of the Company. From the date hereof until the Separation Date, the terms of the First Amended Employment Agreement between you
and the Company, effective June 9, 2020 (the “Employment Agreement”) shall continue in effect, except as expressly
modified by this Agreement. You acknowledge and agree that nothing contained in this Agreement shall give rise to a claim for “Good
Reason” (as defined in the Employment Agreement) under the Employment Agreement. On the Separation Date, you will be deemed to
resign from any and all: (i) officer positions you hold with the Company or any of its Affiliates (as defined in the Employment Agreement),
if any; (ii) memberships you hold on any boards of directors, boards of managers or other governing boards or bodies of the Company or
any of its Affiliates, if any; and (iii) memberships you hold on any of the committees of any such boards or bodies. Subject to earlier
termination as provided for herein, from the Separation Date until June 30, 2022 (the actual period of such consulting services, the
“Consulting Period”), you will serve as a non-employee consultant to the Company on the terms and conditions set forth
in this Agreement.

 

(b)
Duties and Responsibilities. From the date hereof until the Separation Date, you will continue to perform your current duties
for so long as you remain Chief Financial Officer of the Company and will perform such duties as may be reasonably assigned to you from
time to time by the CEO or his designee, including, without limitation, using best efforts in providing the services listed on Appendix
A hereto. You will at all times continue to devote your best efforts to the Company and comply with the Company’s policies
in accordance with the terms of the Employment Agreement.

 

    	 

     

    

 

(c)
Compensation, Benefits and Reimbursements. From the date hereof until the Separation Date, you will continue to receive your base
salary, payable at the rate in effect as of the date hereof ($437,800 per year) and in accordance with the Company’s regular payroll
practices, and to participate in all employee benefit plans and programs of the Company in accordance with the terms of those plans and
programs. You will be eligible to receive an annual bonus in respect of the Company’s 2021 fiscal year, based on achievement of
the performance objectives established by the Compensation Committee of the Board of Directors of the Company and payable at the same
time as bonuses are generally paid to other executives of the Company. In addition, for so long as you are employed or providing services
to the Company hereunder, the Company will pay or reimburse you, in accordance with the Company’s reimbursements procedures and
practices in effect from time to time, for all reasonable business expenses incurred by you in the performance of your duties and responsibilities
to the Company; provided that you submit on a timely basis such documentation and substantiation of those expenses as the Company
may require from time to time.

 

(d)
Equity Awards. Exhibit A hereto sets forth a list of all outstanding stock options previously granted to you by the Company
(the “Equity Awards”). Equity Awards that vest solely based on the passage of time will continue to vest in accordance
with their terms, as set forth in the Company’s 2017 Stock Incentive Plan and the award agreements between you and the Company
evidencing such awards (collectively, the “Equity Documents”), from the date hereof until the end of the Consulting
Period and, to the extent vested and exercisable, will remain outstanding and exercisable for a period of twelve (12) months following
the end of the Consulting Period (but not later than the original term of such Equity Awards). Equity Awards that vest based on the achievement
of performance metrics, to the extent unvested as of the Separation Date, will be forfeited on the Separation Date as set forth on Exhibit
A hereto. All Equity Awards that are outstanding and unvested as of the last day of the Consulting Period will be forfeited on such
date. You acknowledge and agree that any Equity Award that is intended to qualify as an incentive stock option under Section 422 of the
Internal Revenue Code of 1986, as amended (the “Code”) that is exercised more than three months following the Separation
Date will be treated as a non-qualified stock option. Nothing herein, however, constitutes tax advice to you and you are urged to consult
your own independent tax advisors regarding the tax treatment of any Equity Awards that you hold.

 

	2.	 Employment Termination.

 

(a)
Resignation. On the date that the Company’s new Chief Financial Officer commences employment, you will be deemed to resign
your position as Chief Financial Officer of the Company. On the Separation Date, you will be deemed to resign your position as Special
Advisor to the CEO and Chief Financial Officer, shall terminate employment with the Company and shall be deemed to resign from all other
positions you hold with the Company, as provided under Section 1(a) of this Agreement.

 

(b)
Final Compensation. You will receive, in accordance with the provisions of the Employment Agreement, the Accrued Obligations (as
defined in the Employment Agreement). You acknowledge and agree that, upon a termination of your employment on December 31, 2021, you
shall not be entitled to any severance payments or benefits under Section 4.1(d) of the Employment Agreement and shall only be entitled
to the Accrued Obligations.

 

(c)
Employee Benefits. Except for any right you may have to continue participation in the Company’s health, dental and vision
plans under applicable law, which will be communicated to you under separate cover, or as set forth in this Agreement, your active participation
in all employee benefit plans and programs of the Company will terminate as of the Separation Date in accordance with the terms of those
plans and programs. Nothing in this Agreement will affect any vested rights you may have under the Company’s benefit plans and
programs.

 

    	 

     

    

 

(d)
No Further Compensation. You acknowledge and agree that the payments and benefits described in Section 2(b) are in complete satisfaction
of any and all compensation or benefits due to you from the Company, whether for services provided or otherwise, through the Separation
Date, and that, except as expressly provided under this Agreement, no further compensation or benefits are owed or will be paid to you.

 

(e)
Release of Claims. In consideration of your continued service to the Company following the Separation Date as contemplated hereunder,
the payments and benefits set forth in this Agreement and other good and valuable consideration, the receipt and sufficiency of which
you hereby acknowledge, you agree to execute and return to the Company a release of claims in the form attached as Exhibit B to
this Agreement (a “Release”) within the time period specified therein (but in no event prior to the Separation Date).
The execution and non-revocation of such Release is a condition to the receipt of the benefits provided under Section 3 of this Agreement.

 

	3.	Consulting Engagement.

 

(a)
Services. During the Consulting Period, you will be engaged to provide consulting services to the Company relating to assisting
and advising the new Chief Financial Officer and the Finance Department and such other services as may from time to time be requested
by the Company. Your consulting services shall be provided remotely or at the Company’s offices. During the Consulting Period you
will report to the CEO or his designee. You and the Company anticipate that (i) during the portion of the Consulting Period beginning
on January 1, 2022 and ending on March 31, 2022 (the “First Consulting Period”), you will devote approximately eight
(8) hours per week to the performance of the consulting services contemplated by this Agreement (but no more than 104 hours in total
during the First Consulting Period) and (ii) during the portion of the Consulting Period beginning on April 1, 2022 and ending on the
last day of the Consulting Period (the “Second Consulting Period”), you will devote approximately four (4) hours per
week to the performance of the consulting services contemplated by this Agreement (but no more than 52 hours in total during the Second
Consulting Period).

 

(b)
Relationship of the Parties. You and the Company expressly agree that, in providing services under this Section 3 during the Consulting
Period, you will be an independent contractor and will not be an employee or agent of the Company or any other member of the Company.
You agree that you will have no right to make any commitments on behalf of the Company or any of its Affiliates (if any) without the
express written consent of an authorized officer of the Company or its applicable Affiliate (if any).

 

(c)
Services for Others. During the Consulting Period, you may choose to provide services for others, provided that such services
do not (i) give rise to a conflict of interest or otherwise interfere with your obligations to the Company or (ii) violate the Restrictive
Covenants (as defined below).

 

    	 

     

    

 

(d)
Compensation. In consideration of the services that you provide to the Company under this Agreement during the Consulting Period,
the Company will pay you a consulting fee at the rate of (i) $10,000 per month during the First Consulting Period and (ii) $5,000 per
month during the Second Consulting Period, in each case, prorated for partial months. Any consulting fee owed to you will be paid via
ACH on a monthly basis during the first week of the month following the month such fee was earned by you hereunder.

 

(e)
Taxes, Insurance and Benefits. You acknowledge and agree that, as an independent contractor during the Consulting Period, you
will be solely responsible for all insurance and for the payment of all federal, state and local income taxes, Social Security and Medicare
taxes and other legally required payments on any amounts received from the Company. You also acknowledge and agree that, during the Consulting
Period, neither you nor any individual claiming through you will be eligible to actively participate in or receive benefits under any
of the employee benefit plans, programs and arrangements maintained by the Company, other than as expressly provided in this Agreement
as it relates to the Equity Awards.

 

	4.	Early Termination.

 

(a)
Early Termination of Employment. It is expected that your employment with the Company will continue until December 31, 2021. If
your employment terminates prior to December 31, 2021 for any reason, your right to severance payments and benefits, if any, the terms
and conditions of such severance payments and benefits and any notice requirements applicable to you and the Company will be as set forth
in the Employment Agreement.

 

(b)
Early Termination of Consulting Period. It is expected that the period of your consulting services with the Company will continue
until June 30, 2022. Notwithstanding the foregoing or anything to the contrary in this Agreement, the Company may terminate your service
for Cause (as defined in the Employment Agreement) immediately upon notice to you and you or the Company may terminate your service for
any reason upon ninety (90) days’ written notice to the Company. In the event a termination of your consulting service occurs prior
to June 30, 2022, you will receive any earned but unpaid consulting fees through the date of such termination, which shall be paid to
you within thirty (30) days of such termination, and shall not be entitled to any other termination or severance payments or benefits.

 

5.            Withholding. Without
limiting the provisions of Section 3(e) of this Agreement, the Company shall have the right to withhold from all payments made under
this Agreement or otherwise paid or provided to you in respect of your employment with the Company any taxes or any other amounts required
to be withheld by the Company under applicable law, which amounts may be withheld in the discretion of the Company from any amounts payable
under this Agreement.

 

	6.	Continuing Obligations, Cooperation, Non-Disparagement.

 

(a)
You acknowledge and agree that the restrictive covenants set forth in Sections 4.6 and 4.7 of the Employment Agreement and in the Employee
Non-Disclosure and Invention Assignment Agreement between you and the Company, dated as of September 21, 2017 (the “NDIAA”)
(the restrictive covenants in favor the Company or any of its Affiliates to which you are bound, the “Restrictive Covenants”),
shall continue to apply in accordance with their terms. You further acknowledge and agree that the confidentiality and other provisions
contained in the NDIAA shall continue to apply during the Consulting Period as if you had remained employed by the Company.

 

    	 

     

    

 

(b)
You agree to cooperate with the Company and its Affiliates with respect to all matters arising during or related to your employment,
including but not limited to all matters in connection with any governmental investigation, litigation or regulatory or other proceeding
which may have arisen or which may arise following the signing of this Agreement, which such agreement to cooperate shall survive the
termination of your service hereunder. The Company will reimburse your out-of-pocket expenses incurred in complying with Company requests
hereunder, provided such expenses are authorized by the Company in advance.

 

(c)
You agree that you will not, directly or indirectly, at any time disparage or criticize the Company, any of its Affiliates, or any of
their respective management, businesses, products or services, or any of the other Released Parties (as defined below). The Company agrees
(i) to instruct its officers and directors as of the Separation Date not to disparage or criticize you and (ii) not to disparage you
in any authorized corporate communications to any third parties.

 

	7.	 Section 409A.

 

(a)
This Agreement and the payments and benefits provided hereunder are intended to be exempt from, or comply with, the requirements of Section
409A of the Code, and shall be construed consistently with that intent. Notwithstanding the foregoing, in no event shall the Company
have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to be exempt from, or comply
with, the requirements of Section 409A of the Code. Each payment made under this Agreement shall be treated as a separate payment and
the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.

 

(b)
Any reimbursement for expenses payable to you hereunder that would constitute nonqualified deferred compensation subject to Section 409A
of the Code shall be subject to the following additional rules: (i) no reimbursement of any such expense shall affect your right to reimbursement
of any such expense in any other taxable year; (ii) reimbursement of the expense shall be made, if at all, promptly, but not later than
the end of the calendar year following the calendar year in which the expense was incurred; and (iii) the right to reimbursement shall
not be subject to liquidation or exchange for any other benefit.

 

(c)
If you are a “specified employee” (as defined below) at the time of your “separation from service” (as defined
below), any payments or benefits that are payable under this Agreement or otherwise on account of your separation from service that would
(but for this provision) be payable within six (6) months following the date of such separation from service, shall instead be paid on
the next business day following the expiration of such six (6)-month period or, if earlier, upon your death; except (i) to the extent
of amounts that do not constitute a deferral of compensation within the meaning of Section 1.409A-1(b) of the Treasury Regulations (including
without limitation by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable
good faith discretion); (ii) benefits which qualify as excepted welfare benefits pursuant to Section 1.409A-1(a)(5) of the Treasury Regulations;
or (iii) other amounts or benefits that are not subject to the requirements of Section 409A of the Code.

 

    	 

     

    

 

(d)
For purposes of this Agreement, the term “separation from service” shall have the meaning set forth in Section 1.409A-1(h)
of the Treasury Regulations (after giving effect to the presumptions contained therein), and the term “specified employee”
means an individual determined by the Company to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations.

 

8.            Miscellaneous. This Agreement constitutes the entire agreement between you and the Company, and replaces all prior and contemporaneous
agreements, whether written or oral, with respect to the subject matter of this Agreement and all related matters; it being understood,
for the avoidance of doubt, that the Restrictive Covenants shall remain in effect in accordance with their terms. This Agreement may
not be amended and no breach will be deemed waived unless agreed to in a signed writing by you and an authorized officer of the Company.
The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision
of this Agreement. This is a New Jersey contract and shall be governed and construed in accordance with the laws of New Jersey, without
regard to any conflict of laws principles that would result in the application of the laws of another jurisdiction. The governing law
and jurisdiction provisions of the Employment Agreement shall apply to this Agreement. This Agreement may be executed in separate counterparts
(including by electronically delivered .pdf files or copies of manually signed signature pages), each of which will be deemed to be an
original and all of which taken together will constitute one and the same agreement.

 

[Remainder
of page intentionally left blank.]

 

    	 

     

    

 

If
the foregoing is acceptable to you, please sign this letter in the space provided and return it to the Company. The enclosed copy of
this letter, which you should also sign and date, is for your records.

 

	 	Sincerely,
	 	 	 
	 	PROVENTION
    BIO, INC.
	 	 	 
	 	By:	/s/:
    Ashleigh Palmer
	 	 	Ashleigh
    Palmer
	 	 	Chief
    Executive Officer
	 	 	 
	 	Date:	11/01/2021

 

	Accepted
    and agreed:	 
	 	 	 
	 	/s/:
    Andrew Drechsler	 
	 	Andrew
    Drechsler	 
	 	 	 
	Date:	11/01/2021	 

 

[Signature
Page to Transition Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]